Harbin Medical University

This study looks at whether heart attack patients with mild blockages can be treated with medication alone instead of getting a stent. About 2,000 people will be randomly assigned to receive either standard medication or medication plus a stent. The goal is to see if medication a…

This early-phase study tests whether adding pirfenidone to standard immunotherapy (camrelizumab) and chemotherapy can shrink tumors in 12 people with advanced triple-negative breast cancer. Participants must have already tried first-line treatment. The goal is to see how many pat…

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a PARP inhibitor (olaparib) and chemotherapy (paclitaxel) in 20 women with early high-risk triple negative breast cancer that has a specific genetic marker (HRD positive). The goal is to…

This study tests whether a combination of an oral chemotherapy (paclitaxel solution) and a targeted drug (fruquintinib) can help control advanced stomach or gastroesophageal junction cancer after the first treatment stops working. About 150 adults whose cancer has worsened after …

This early-phase study tests a combination of two drugs—aipalirovorelizumab (QL1706) and fruquintinib—in 18 adults with a specific type of advanced colorectal cancer (pMMR/MSS) that has not responded to at least two prior treatments. The goal is to see if the combination can shri…

This study tests whether using a special heart CT scan to guide intensive treatment can reduce major heart problems like heart attacks and strokes compared to standard care. About 15,000 high-risk adults aged 40-75 in rural China will take part. The goal is to see if this persona…

This study tests a mobile app called "Heart Voice: Starry Journey" designed to help parents and caregivers of children with autism feel more flexible and less stressed. About 52 caregivers will use the app for 6 weeks, doing interactive stories and exercises based on acceptance a…